1. Home
  2. CNEY vs ENTO Comparison

CNEY vs ENTO Comparison

Compare CNEY & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNEY
  • ENTO
  • Stock Information
  • Founded
  • CNEY 2018
  • ENTO 2014
  • Country
  • CNEY China
  • ENTO United States
  • Employees
  • CNEY N/A
  • ENTO N/A
  • Industry
  • CNEY Major Chemicals
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNEY Industrials
  • ENTO Health Care
  • Exchange
  • CNEY Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • CNEY 2.1M
  • ENTO 1.9M
  • IPO Year
  • CNEY 2021
  • ENTO 2016
  • Fundamental
  • Price
  • CNEY $2.87
  • ENTO $0.52
  • Analyst Decision
  • CNEY
  • ENTO
  • Analyst Count
  • CNEY 0
  • ENTO 0
  • Target Price
  • CNEY N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • CNEY 251.7K
  • ENTO 3.2M
  • Earning Date
  • CNEY 01-01-0001
  • ENTO 06-17-2025
  • Dividend Yield
  • CNEY N/A
  • ENTO N/A
  • EPS Growth
  • CNEY N/A
  • ENTO N/A
  • EPS
  • CNEY N/A
  • ENTO N/A
  • Revenue
  • CNEY $50,957,974.00
  • ENTO N/A
  • Revenue This Year
  • CNEY N/A
  • ENTO N/A
  • Revenue Next Year
  • CNEY N/A
  • ENTO N/A
  • P/E Ratio
  • CNEY N/A
  • ENTO N/A
  • Revenue Growth
  • CNEY N/A
  • ENTO N/A
  • 52 Week Low
  • CNEY $2.53
  • ENTO $0.19
  • 52 Week High
  • CNEY $40.00
  • ENTO $2.64
  • Technical
  • Relative Strength Index (RSI)
  • CNEY 42.70
  • ENTO 69.29
  • Support Level
  • CNEY $2.60
  • ENTO $0.35
  • Resistance Level
  • CNEY $3.09
  • ENTO $0.50
  • Average True Range (ATR)
  • CNEY 0.28
  • ENTO 0.08
  • MACD
  • CNEY -0.00
  • ENTO 0.01
  • Stochastic Oscillator
  • CNEY 47.22
  • ENTO 51.85

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: